NovaBridge Biosciences
NBP
$2.06
-$0.04-1.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 12/31/2024 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 134.87% | -26.76% | -68.00% | 3.94% | 158.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 445.21% | -27.58% | -58.49% | 0.71% | 122.88% |
| Operating Income | -445.21% | 27.58% | 58.49% | -1.94% | -123.79% |
| Income Before Tax | -571.87% | 66.68% | 38.44% | 67.50% | -119.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -571.87% | 66.68% | 38.44% | 67.50% | -119.00% |
| Earnings from Discontinued Operations | -- | -- | -- | 106.27% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -571.87% | 66.68% | -121.65% | 85.34% | 72.91% |
| EBIT | -445.21% | 27.58% | 58.49% | -1.94% | -123.79% |
| EBITDA | -446.00% | 27.60% | 58.33% | -2.37% | -123.70% |
| EPS Basic | -374.08% | 73.94% | -121.46% | 85.01% | 72.33% |
| Normalized Basic EPS | -362.38% | 22.24% | 38.99% | 55.12% | -116.16% |
| EPS Diluted | -374.08% | 73.94% | -121.46% | 85.01% | 72.33% |
| Normalized Diluted EPS | -362.38% | 22.24% | 38.99% | 55.12% | -116.16% |
| Average Basic Shares Outstanding | 41.77% | 27.87% | 0.95% | -2.12% | -2.12% |
| Average Diluted Shares Outstanding | 41.77% | 27.87% | 0.95% | -2.12% | -2.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |